The DB Phase will include a Screening Visit to establish protocol eligibility and disease characteristics. The Baseline Visit will confirm eligibility prior to randomization and treatment. The DB Phase of the study will end on the date of data cut-off for the primary analysis of PFS, which will occur when the target number of events (175 disease Progression as centrally assessed or deaths reached) between the two treatment groups has been observed.